anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Vocal fold (VF) scarring, a complex problem in laryngology, results from injury and inflammation of the layered architecture of the VFs. The resultant voice hoarseness, for which successful therapeutic options are currently limited, affects the patient's quality of life. A promising strategy to reverse this disorder is the use of antifibrotic drugs. The present study proposes a novel microbead-embedded injectable hydrogel that can sustain the release of the anti-fibrotic drug pirfenidone (PFD) for vocal fold scarring. Microbeads were developed using sodium alginate and gelatin, which were further embedded into a biomimetic and tissue adhesive gellan gum (GG) hydrogel. The microbead-embedded hydrogel exhibited improved injectability, viscoelasticity, tissue adhesiveness, degradability, and swelling compared to the hydrogel without beads. Additionally, the bead-embedded hydrogel could sustain the release of the PFD for a week. In vitro studies showed that the drug-loaded hydrogel could reduce the migration and proliferation of fibroblast cells in a dose-dependent manner. In summary, this study demonstrates the potential of a PFD-loaded injectable hydrogel with enhanced viscoelastic and tissue-adhesive properties for vocal fold scarring applications.
NEW MATERIAL:A 3,4-dihydromilbemycin D derivative of formula I (R is oxo or OH). EXAMPLE:5-Oxo derivative of 3,4-dihydromilbemycin D. USE:An excellent acaricide and anthelmintic agent. PROCESS:A compound of formula II obtained by oxidizing milbemycin D is reacted with a trisubstituted hydrosilane in the presence of a transition metallic catalyst to give a silyl enol ether derivative, which is then treated with an acid or alkali to prepare a compound of formula I (R is oxo). The resultant compound is treated with a reducing agent, e.g. sodium boron hydride, to prepare the compound of formula I (R is 5beta-hydroxy). A 5alpha-hydroxy derivative is obtained from the resultant 5beta-hydroxy derivative.
Patients with squamous lung cancer receive nivolumab IV over 30 minutes on day 1, cisplatin IV over 60-120 minutes on day 1, and gemcitabine hydrochloride IV over 1 hour on days 1 and 8. Courses repeat every 3 weeks for up to 9 weeks in the absence of disease progression or unacceptable toxicity.
Circulating cancer stem cells (CCSCs) are subpopulations of cancer cells with high tumorigenicity, chemoresistance, and metastatic potential, which are also major drivers of disease progression. Herein, to achieve the prediction of tumor diagnosis and progression in colorectal cancer (CRC), a new, automated, and portable lateral displacement patterned pump-free (LP) microfluidic chip (LP-chip) with the CoPt3 nanozyme was established for CCSC capture and detection in peripheral blood and feces samples ex vivo. In this design, CoPt3@HA probes with functions of magnetic separation and colorimetric signal transduction by peroxidase-mimicking activity were applied for the capture of CCSCs and signal output in clinical samples. The generated colors of polydopamine (PDA) were quantifiable through the smartphone APP and visualizable by the naked eye in the test line (T line) and control line (C line) of the LP-chip. In the optimal experimental conditions, the CCSC concentration was sensitive to change in the range 0-105 cells mL-1, with a detection limit of 3 cells mL-1 (S/N = 3). Preliminary studies of clinical samples suggest that the platform has the potential for prediction of colorectal cancer progression and poor prognosis. Overall, the LP-chip provides potential strategies for timely diagnosis, therapeutic monitoring, and recurrence prediction to improve home-based patient care.
The subject invention pertains to materials and methods for the prevention and treatment of gastrointestinal diseases, including inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. Therapeutic compositions of the invention include compositions that can neutralize hydrogen peroxide, such as reducing agents and oxidizing agents. In one embodiment, a therapeutic composition of the invention comprises a reducing agent such as sodium thiosulfate. Therapeutic compositions of the invention can optionally include compounds with antibacterial activity, compositions that inhibit bacterial adherence to cells and tissue, compositions that inhibits epithelial lipid peroxidation, compositions that add viscosity to a solution, compositions that inhibit most cells, and/or compositions that help to seal or repair tight junctions between cells of the colonic epithelium of the gastrointestinal tract. Methods of the invention include administration of compounds or compositions of the invention. In one embodiment, compounds or compositions of the invention are rectally instilled in a patient.
Method/Design. This study will be a single-site, three-arm, randomized, controlled trial. College students (N=51) with elevated depression and/or anxiety will be randomized to either external qigong (EQ), mindfulness meditation (MM), or psychoeducation (PE). Each intervention will be applied for 30 minutes, once a week for three weeks in a community setting. The co-primary outcomes, depression and anxiety, and the secondary outcome, intention to persist in college, will be assessed by a blinded researcher at baseline, one-week post treatment, and one-month follow-up. Change in sense of connection during the treatment session, measured with a comprehensive battery of self-report indices, will be the primary therapeutic mechanism.

Aims and Objectives. The proposed project's central hypothesis is that EQ will increase students' mental health and intention to persist in college by balancing the flow of energy in their bodies. Aim 1. Examine EQ's acceptability in a sample of college students with depression and/or anxiety. Hypothesis: Student retention (i.e., attendance in both treatment sessions) and self-reported treatment acceptability will be better for EQ relative to PE. EQ and MM will demonstrate equivalent acceptability. Aim 2. Determine EQ's effect on anxiety, depression (co-primary outcomes), and intention to persist in college (secondary outcome) over time. Hypothesis: EQ will decrease depression and anxiety while increasing intention to persist in college relative to PE from baseline to one-month follow-up. The co-primary and secondary outcome scores will not differ between EQ and MM. Aim 3. Investigate EQ's immediate effect on students' sense of connection (therapeutic mechanism). Hypothesis: EQ will increase students' sense of connection relative to PE during the treatment sessions. EQ and MM will have equivalent effects on sense of connection.
PURPOSE:To provide the subject new compounds useful as an antineoplastic agent exhibiting a wide antineoplastic spectrum. CONSTITUTION:Compounds of formula I (X is O or S). The compound of formula I can be obtained by the following method. The amino group and the carboxylic group of L-homoserine represented by formula II are initially protected in order and the primary hydroxyl group is then oxidized to obtain an aldehyde compound. The resultant aldehyde compound is subsequently subjected to an unsaturated bond-formation reaction to obtain an olefin compound of formula III. The obtained olefin compound is subjected to Michael addition reaction and the protecting t-butyl ester group and the protecting BOC group are then removed. The resultant compound is subjected to cyclization to obtain a cyclic compound of formula IV. The obtained cyclic compound is converted to a dihydro-2-pyridone compound by oxidation elimination and the methyl ester group is subsequently hydrolyzed to obtain the compound of formula I.
Adverse reactions to epinephrine include transient, moderate anxiety; apprehensiveness; restlessness; tremor; weakness; dizziness; sweating; palpitations; pallor; nausea and vomiting; headache; and/or respiratory difficulties. These symptoms occur in some persons receiving therapeutic doses of epinephrine, but are more likely to occur in patients with hypertension or hyperthyroidism. Arrhythmias, including fatal ventricular fibrillation, have been reported in patients with underlying cardiac disease or certain drugs (see PRECAUTIONS, Drug Interactions). Rapid rises in blood pressure have produced cerebral hemorrhage, particularly in elderly patients with cardiovascular disease. Angina may occur in patients with coronary artery disease. The potential for epinephrine to produce these types of adverse reactions does not contraindicate its use in an acute life-threatening allergic reaction. 

Accidental injection into the digits, hands or feet may result in loss of blood flow to the affected area (see WARNINGS). Adverse events experienced as a result of accidental injections may include increased heart rate, local reactions including injection site pallor, coldness and hypoaesthesia or injury at the injection site resulting in bruising, bleeding, discoloration, erythema or skeletal injury.
PURPOSE: Provided is an inhibition agent of tyrosinase composed of the extract of Houttuynia cordata Thunb. Also, a cosmetic composition containing the same is provided which composition has excellent effects on skin whitening effects and excellent safety. CONSTITUTION: Tyrosinase inhibition agent is characteristically composed of the extract obtained from the roots of Houttuynia cordata Thunb. Its manufacturing method comprises the steps of: adding 20 L of at least one solvent selected from water, ethanol, methanol, acetone, propanol, and 1,3-butyleneglycol to Houttuynia cordata Thunb; extracting it at 40 deg. C for 8 hours then filtering the extract; and maturing the filtrate at 20-25 deg.C for 7 days. The cosmetic composition contains the extract of Houttuynia cordata Thunb in the amount of 0.0005-20%(w/w) based on its dry weight.
Methods and compositions for treatment of a patient suffering from a form of peripheral neuropathy are disclosed. The method comprises administering to the patient any one of the following combinations of components: I. A, B and C; II. A and B; III. B and C; IV. A and C, wherein A is an antidepressant or a monoamine oxidase inhibitor, B is vitamin B12, and C is a precursor or inducer of a neurotransmitter, e.g. L-phenylalanine.
Our objective is to explore the protective effect of Dexmedetomidine on brain apoptosis and its mechanism through TREK-1 pathway. Forty male Sprague-Dawley rats were allocated into four groups: Sham, Cerebral Ischemia/Reperfusion Injury (CIRI), 50 µg/kg Dex, and 100 µg/kg Dex. A rat model of middle cerebral artery occlusion (MCAO) was employed to simulate cerebral embolism. Primary cortical neurons were exposed to Dex for 48 h, with some receiving additional treatment with 100 µM yohimbine hydrochloride (YOH) or TREK-1 small interfering RNA (siRNA). Neuronal damage was assessed using hematoxylin and eosin (HE) staining. Cell viability and apoptosis were measured by Cell Counting Kit-8 (CCK8) and flow cytometry, respectively. Protein and gene expression levels of Bcl-2, Bax, and TREK-1 were determined by Western blot and real-time polymerase chain reaction (PCR). Histopathological changes revealed that Dex treatment at both 50 µg/kg and 100 µg/kg significantly mitigated neuronal damage compared to the CIRI group. YOH treatment and Trek1 siRNA significantly reduced cell viability (p < 0.05). The mRNA expression and protein levels of TREK-1 and Bax were remarkably increased, while mRNA expression and protein levels of Bcl-2 was seriously decreased after CIRI modeling. In contrast, Dex treatment at both concentrations led to decreased TREK-1 and Bax expression and increased Bcl-2 expression in primary cortical neurons. Addition of 100 µM YOH and Trek1 siRNA reversed the effects of Dex on apoptosis-related genes (p < 0.05). Dex exerts neuroprotective effects through the TREK-1 pathway in vivo and in vitro.
FIELD: medicine, pharmacy. SUBSTANCE: pharmaceutical preparation has growth hormone and an effective amount of stabilizing amino acid - asparagine. The use of asparagine provides high stability of the preparation to prevent deamidination, oxidation and peptide bond cleavage. Preparation can be transported as the lyophilized form or as a solution at an environment temperature. EFFECT: high quality and effectiveness of preparation. 7 cl, 1 tbl
PROBLEM TO BE SOLVED: To obtain an emulsion-like or creamy emulsified composition and a dermal preparation for external use having excellent stability and safety, low irritation to the skin and excellent humectant property and use feeling without mixing any surfactant. SOLUTION: An emulsified composition is prepared by containing 1-20wt.% α- cyclodextrin, 0.1-20wt.% of a polyoxyethylene gloycol and 1-50wt.% of an oily component (e.g. silicone oil), and a derenal preparation for external use can be prepared by containing the emulsified composition. The resultant emulsified composition and the dermal preparation for external use are miscible with various prescription systems, and are excellent in emulsifying stability and enhance stability of the system. Furthermore, these are excellent in a stability for a passage of time, cause only low-irritation to the skin and to eyes and have no stickiness nor creakiness, and have wet and substantial use feeling. The system is stable in a wide pH range because of containing no ionic group in the molecules of the essential components.  Furthermore, a coated film formed from the system after use exhibits water repellent property in spite of on O/W type emulsion, thus the objective preparation having excellent water resistance is obtained.
PURPOSE:To obtain a new compound, having excellent protecting actions on endotoxin shock and treating actions on nephritis and useful as a preventing and therapeutic agent for the endotoxin shock or nephritis developed in, e.g. a patient suffering from severe infectious diseases due to Gram-negative bacteria. CONSTITUTION:This compound of formula I [R<1> is an aryl, a lower alkyl, etc.; R<2> is H, a lower alkyl, etc.; X is (thio)carbonyl; Alk is a single direct bond or a lower alkylene; the dotted line indicates the presence(absence) of double bond] or its salt, e.g. 2-butyrylamino-5-[4,5-dihydropyridazin-3(2H)-on-6- yl]indane. The compound is obtained by reacting an indane compound of formula II or its salt with a compound of the formula R<1>-X-OH, its salt or reactional derivative at preferably -10 deg.C to ambient temperature. Furthermore, a compound other than a compound in which R<2> is H; Alk is single direct bond and the dotted line indicates the absence of the double bond in the compound of formula II is a new compound an obtained by reacting, e.g. a compound of formula III (R<21> is H or a lower alkyl) with hydrazine.
The introductory letter to patients will allow them an opportunity to "opt-out" of the study using a toll-free number. If they do not opt-out within 2 weeks of receiving the letter, the IVR system will make up to 15 call attempts over a 2 week period to reach the patient. The system will make outbound calls during preset hours. The system continuously checks the call list for the next scheduled call. Once contact is made, the spoken script greets the patient by name, authenticates identify, and will ask the patient the programmed questions. The IVR server will send completed family history assessments to the patients EHR as an HL7 compliant summary note as well as transmitting the separate coded responses for each condition/ family member to coded family history fields in the EHR.
Inventors observe that the NButGT treatment increases the O-GlcNAcylation levels of cardiac proteins (p<0.05). Mean arterial pressure decreases 5 hours after ECC procedure compared to the sham group (sham: 95.7 ± 3.7; ECC: 69.8 ± 7.7; mmHg; p<0.05). The NButGT treatment tends to increase the mean arterial pressure compared to the ECC group (NButGT: 90.8 ± 10.3;mmHg; p = 0.11). ECC procedure is associated with an organism injury with an increase in lactates, creatinine, blood urea nitrogen and bicarbonates levels 5 hours after ECC procedure (p<0.05). NButGT treatment tends to reduce lactates and creatinine levels and decreases blood urea nitrogen and arterial bicarbonates 5 hours after ECC procedure (p<0.05). Accordingly, the present invention relates to a method for increasing O-GlcNAcylation levels in a subject having or is susceptible to have an extracorporeal circulation comprising administering said subject with a therapeutically effective amount of a compound that increases O-GlcNAcylation levels.
A preparation for transcutaneous use of the scalp for the restoration of the natural colour of the hair, or for preventing it becoming grey, comprises (a) one or more of the following:-mono- or poly-hydroxyphenyl amino acids, or salts thereof with bases (i.e. a metal or ammonium salt, or a salt of an organic base) or with acids, or adrenaline or its compounds with acids and (b) tyrosinase, these ingredients being incorporated in a carrier, e.g. alcohol and/or glycerin, or a fatty base, as in an ointment, or an anhydrous base as in a brilliantine.  Oil-in-water emulsions may also be employed.  The preparations may also contain liver and/or yeast extracts, vegetable extracts containing an orthodiphenol combined with 5 : 7-3 : 4 dihydroxychromanes, e.g. quercetine its glycoside quercitrine found in chamomile extract, or the extract itself. Examples of amino acids used are 3 : 4 dihydroxyphenylalanine and tyrosine.
The Enrollment Kit and Time1 Kit will be administered at enrollment, Time2 Kit will be administered before discharge and Time 3 kit after 6 and 18 months post hospitalization (see Detailed description and Study Protocol). The interventions will be Treatment as usual.
All participants completed 2 weeks of the study. Baseline reflex measurements will be collected during the first week of the study (Visits 1-4). No dry needling will occur during this week, with the aim of tracking any natural variability in nervous system excitability at the same time points as reflex measurements during the intervention week. All participants who participated in baseline reflex measurements during week 1 will continue to the second week of the study (Visits 5-7). Participants will receive dry needling to relieve spasticity in the target calf muscle (middle gastrocnemius) during Visit 5. The study team will examine the effects of this treatment on the nervous system by performing assessments just prior to DDN, immediately after DDN, 90 minutes after DDN, 24 hours after DDN, and 72 hours after DDN. These assessments will examine how you move your leg and how your nervous system responds to non-invasive nerve stimulation.
The present invention relates to novel colorectal cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as “colorectal cancer antigens,” and the use of such colorectal cancer antigens for detecting disorders of the colon and/or rectum, particularly the presence of colorectal cancer and colorectal cancer metastases. More specifically, isolated colorectal cancer associated nucleic acid molecules are provided encoding novel colorectal cancer associated polypeptides. Novel colorectal cancer polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human colorectal cancer associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the colon and/or rectum, including colorectal cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.
Silica nanoparticles are increasingly considered for drug delivery applications. These applications require an understanding of their biocompatibility, including their interactions with the immune system. However, systematic studies for silica nanoparticle immunological safety profiles are lacking. To fill this gap, we conducted an in vitro study investigating various aspects of silica nanoparticles' interactions with blood and immune cells. Four types of silica nanoparticles with variations in size and porosity were studied. These included nonporous Stöber silica nanoparticles with average diameters of approximately 50 and 100 nm (SNP50 and SNP100), mesoporous silica nanoparticles of approximately 100 nm (Meso100), and hollow mesoporous silica nanoparticles of approximately 100 nm (HMSNP100) in diameter, respectively. The hematological compatibility was assessed using hemolysis, complement activation, platelet aggregation, and plasma coagulation assays. The effects of nanoparticles on immune cell function were studied using in vitro phagocytosis, chemotaxis, natural killer cell cytotoxicity, leukocyte proliferation, human lymphocyte activation, colony-forming unit granulocyte-macrophage, and leukocyte procoagulant activity assays. The in vitro findings suggest that at high concentrations, corresponding to the in vivo human dose of 40 mg/kg, silica nanoparticles demonstrated an array of immunotoxic effects that depended on their physicochemical properties. However, all types of silica nanoparticles studied were not immunotoxic at concentrations corresponding to lower doses (≤ 8 mg/kg) comparable to that of nanocarriers in other nanomedicines currently used in the clinic. These findings are promising for using silica nanoparticles for the systemic delivery of bioactive and imaging agents.
The present invention relates to a chronotherapeutically combined pharmaceutical formulation for preventing and treating cardiovascular diseases, which is based on the principle of administering a plurality of drugs at certain time intervals (chronotherapy). Specifically, the combined pharmaceutical formulation comprises a HMG-CoA reductase inhibitor, such as simvastatin, and aspirin. Because the combined pharmaceutical formulation was developed based on the principle of administering drugs at certain time intervals, so-called chronotherapy, it shows an excellent effect of preventing or treating cardiovascular disease compared to those of the individual administration and simultaneous administration of the single preparations. Also, it is a once-daily dosage form which increases the medication compliance of patients. Particularly, even though the content of aspirin in the combined pharmaceutical formulation is reduced, the platelet aggregation inhibitory effect of aspirin in the combined pharmaceutical formulation is equal to that of the amount of aspirin used in the prior art, while the aspirin in the combined pharmaceutical formulation shows a antihypertensive effect. In addition, the chronotherapeutically combined pharmaceutical formulation allows the two drugs, which interact with each other, to be stored for a long period of time, and the combined pharmaceutical formulation ensures the human body-safety and efficacy of the two drugs.